| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Taro Kishi, Reiji Yoshimura, Kenji Sakuma, Makoto Okuya, Nakao Iwat. Lurasidone, olanzapine, and quetiapine extended-release for bipolar depression: A systematic review and network meta-analysis of phase 3 trials in Japan. Neuropsychopharmacology reports. vol 40. issue 4. 2021-09-07. PMID:32902200. |
lurasidone, olanzapine, and quetiapine extended-release for bipolar depression: a systematic review and network meta-analysis of phase 3 trials in japan. |
2021-09-07 |
2023-08-13 |
Not clear |
| Taro Kishi, Reiji Yoshimura, Kenji Sakuma, Makoto Okuya, Nakao Iwat. Lurasidone, olanzapine, and quetiapine extended-release for bipolar depression: A systematic review and network meta-analysis of phase 3 trials in Japan. Neuropsychopharmacology reports. vol 40. issue 4. 2021-09-07. PMID:32902200. |
this systematic review and random-effect model, network meta-analysis of the phase 3 trials in japan assessed the efficacy and safety profile of lurasidone compared with olanzapine and quetiapine extended-release (que-xr) for the treatment of bipolar depression. |
2021-09-07 |
2023-08-13 |
Not clear |
| Tadafumi Kato, Jun Ishigooka, Mari Miyajima, Kei Watabe, Tomohiro Fujimori, Takahiro Masuda, Teruhiko Higuchi, Eduard Viet. Double-blind, placebo-controlled study of lurasidone monotherapy for the treatment of bipolar I depression. Psychiatry and clinical neurosciences. vol 74. issue 12. 2021-09-06. PMID:32827348. |
double-blind, placebo-controlled study of lurasidone monotherapy for the treatment of bipolar i depression. |
2021-09-06 |
2023-08-13 |
Not clear |
| Tadafumi Kato, Jun Ishigooka, Mari Miyajima, Kei Watabe, Tomohiro Fujimori, Takahiro Masuda, Teruhiko Higuchi, Eduard Viet. Double-blind, placebo-controlled study of lurasidone monotherapy for the treatment of bipolar I depression. Psychiatry and clinical neurosciences. vol 74. issue 12. 2021-09-06. PMID:32827348. |
previous studies conducted primarily in the usa and europe have demonstrated the efficacy and safety of lurasidone 20-120 mg/day for the treatment of bipolar i depression. |
2021-09-06 |
2023-08-13 |
Not clear |
| Tadafumi Kato, Jun Ishigooka, Mari Miyajima, Kei Watabe, Tomohiro Fujimori, Takahiro Masuda, Teruhiko Higuchi, Eduard Viet. Double-blind, placebo-controlled study of lurasidone monotherapy for the treatment of bipolar I depression. Psychiatry and clinical neurosciences. vol 74. issue 12. 2021-09-06. PMID:32827348. |
the aim of the current study was to evaluate the efficacy and safety of lurasidone monotherapy for the treatment of bipolar i depression among patients from diverse ethnic backgrounds, including those from japan. |
2021-09-06 |
2023-08-13 |
Not clear |
| Marcin Siwek, Aleksandra Gorostowic. Lurasidone in Therapy of Treatment-resistant Ultra-rapid Cycling Bipolar Disorder: Case Report. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 19. issue 3. 2021-09-01. PMID:34294628. |
lurasidone is an atypical antipsychotic approved for the treatment of schizophrenia and bipolar depression. |
2021-09-01 |
2023-08-13 |
Not clear |
| Michael Tocco, Andrei Pikalov, Courtney Zeni, Robert Goldma. Effect of Lurasidone on Manic Symptoms and Treatment-Emergent Mania in Adult and Pediatric Populations with Bipolar Depression. CNS spectrums. vol 26. issue 2. 2021-07-23. PMID:34127089. |
effect of lurasidone on manic symptoms and treatment-emergent mania in adult and pediatric populations with bipolar depression. |
2021-07-23 |
2023-08-13 |
Not clear |
| Michael Tocco, Andrei Pikalov, Courtney Zeni, Robert Goldma. Effect of Lurasidone on Manic Symptoms and Treatment-Emergent Mania in Adult and Pediatric Populations with Bipolar Depression. CNS spectrums. vol 26. issue 2. 2021-07-23. PMID:34127089. |
lurasidone is approved for the treatment of bipolar depression both as monotherapy and adjunctive therapy with lithium or valproate (li/vpa). |
2021-07-23 |
2023-08-13 |
Not clear |
| Michael Tocco, Andrei Pikalov, Courtney Zeni, Robert Goldma. Effect of Lurasidone on Manic Symptoms and Treatment-Emergent Mania in Adult and Pediatric Populations with Bipolar Depression. CNS spectrums. vol 26. issue 2. 2021-07-23. PMID:34127089. |
the aim of these analyses was to evaluate the prevalence of treatment-emergent mania (tem) and worsening of mania symptom severity in clinical trials of both adult and pediatric patients with bipolar depression treated with lurasidone. |
2021-07-23 |
2023-08-13 |
Not clear |
| Manpreet Singh, Michael Tocco, Edward Schweizer, Andrei Pikalo. Long-Term Effectiveness of Lurasidone in Pediatric Bipolar Depression: Response, Remission and Recovery. CNS spectrums. vol 26. issue 2. 2021-07-23. PMID:34127107. |
long-term effectiveness of lurasidone in pediatric bipolar depression: response, remission and recovery. |
2021-07-23 |
2023-08-13 |
Not clear |
| Manpreet Singh, Michael Tocco, Edward Schweizer, Andrei Pikalo. Long-Term Effectiveness of Lurasidone in Pediatric Bipolar Depression: Response, Remission and Recovery. CNS spectrums. vol 26. issue 2. 2021-07-23. PMID:34127107. |
lurasidone has been approved by the fda as monotherapy for bipolar depression in pediatric patients ages 10-17 years. |
2021-07-23 |
2023-08-13 |
Not clear |
| Manpreet Singh, Michael Tocco, Edward Schweizer, Andrei Pikalo. Long-Term Effectiveness of Lurasidone in Pediatric Bipolar Depression: Response, Remission and Recovery. CNS spectrums. vol 26. issue 2. 2021-07-23. PMID:34127107. |
the aim of the current post-hoc analysis was to evaluate the long-term efficacy of lurasidone in achieving response or remission in children and adolescents with bipolar depression followed over a two-year period. |
2021-07-23 |
2023-08-13 |
Not clear |
| Leslie Citrome, Michael Tocco, Courtney Zeni, Andrei Pikalov, Robert Goldma. Assessing the Benefit-Risk Ratio of Approved Treatments for Bipolar Depression Using Likelihood to be Helped or Harmed (LHH) Analyses. CNS spectrums. vol 26. issue 2. 2021-07-23. PMID:34127111. |
four medications are fda approved for bipolar depression: lurasidone (lur), cariprazine (car), quetiapine ir & xr (que), and olanzapine-fluoxetine combination (ofc). |
2021-07-23 |
2023-08-13 |
Not clear |
| Jun Ishigooka, Tadafumi Kato, Mari Miyajima, Kei Watabe, Takahiro Masuda, Katsuhiko Hagi, Teruhiko Higuch. Corrigendum to "Lurasidone in the Long-Term Treatment of Bipolar I Depression: A 28-week Open Label Extension Study". [Journal of Affective Disorders 281 (2021) 160-167]. Journal of affective disorders. vol 292. 2021-07-14. PMID:34144849. |
corrigendum to "lurasidone in the long-term treatment of bipolar i depression: a 28-week open label extension study". |
2021-07-14 |
2023-08-13 |
Not clear |
| Ivan Arnold, Julia Dehning, Anna Grunze, Armand Hausman. Old Age Bipolar Disorder-Epidemiology, Aetiology and Treatment. Medicina (Kaunas, Lithuania). vol 57. issue 6. 2021-07-05. PMID:34201098. |
lamotrigine and lurasidone could be considered in bipolar depression. |
2021-07-05 |
2023-08-13 |
Not clear |
| Robert M Post, Heinz Grunz. The Challenges of Children with Bipolar Disorder. Medicina (Kaunas, Lithuania). vol 57. issue 6. 2021-07-05. PMID:34207966. |
lithium and atypical antipsychotics are effective in mania, but treatment of depression remains obscure, with the exception of lurasidone, for children ages 10-17. |
2021-07-05 |
2023-08-13 |
Not clear |
| Zhengchao Dong, Michael F Grunebaum, Martin J Lan, Vashti Wagner, Tse-Hwei Choo, Matthew S Milak, Tarek Sobeih, J John Mann, Joshua T Kantrowit. Relationship of Brain Glutamate Response to D-Cycloserine and Lurasidone to Antidepressant Response in Bipolar Depression: A Pilot Study. Frontiers in psychiatry. vol 12. 2021-06-22. PMID:34149476. |
relationship of brain glutamate response to d-cycloserine and lurasidone to antidepressant response in bipolar depression: a pilot study. |
2021-06-22 |
2023-08-13 |
Not clear |
| Harika Modugula, Anoop Kuma. Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression. CNS & neurological disorders drug targets. vol 19. issue 2. 2021-06-14. PMID:32124704. |
risk analysis of lurasidone in patients with schizophrenia and bipolar depression. |
2021-06-14 |
2023-08-13 |
Not clear |
| Harika Modugula, Anoop Kuma. Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression. CNS & neurological disorders drug targets. vol 19. issue 2. 2021-06-14. PMID:32124704. |
lurasidone was approved by the united states food and drug administration (fda) for the treatment of schizophrenia, as well as for the treatment of bipolar depression. |
2021-06-14 |
2023-08-13 |
Not clear |
| Harika Modugula, Anoop Kuma. Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression. CNS & neurological disorders drug targets. vol 19. issue 2. 2021-06-14. PMID:32124704. |
in conclusion, lurasidone is a novel and efficacious pharmacological treatment for bipolar depression and schizophrenia. |
2021-06-14 |
2023-08-13 |
Not clear |